Bastide le Confort Medical (BLC) AI Stock Analysis

• Market Cap: €215.99M
• Dividend Yield: N/A
• Average Volume (3M): 6.91K
• Price to Earnings (P/E): 128.2
• Beta (1Y): 0.62
• Revenue Growth: 3.24%
• EPS Growth: -75.05%
• Country: FR
• Employees: 3,635
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Distribution
• EPS (TTM): 0.23
• Shares Outstanding: 7,361,478
• 10 Day Avg. Volume: 8,449
• 30 Day Avg. Volume: 6,914
• PEG Ratio: 4.62
• Price to Book (P/B): 2.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: ―

The overall stock score is influenced primarily by a stable technical outlook, with the stock trading above key moving averages. However, financial performance issues such as negative net income and high leverage, combined with a high P/E ratio, suggest potential risks. The absence of earnings call data and corporate events means these factors did not contribute to the score.

Bastide le Confort Medical Business Overview & Revenue Model

Company Description

Bastide le Confort Medical (BLC) is a French company specializing in the distribution and rental of medical equipment and home healthcare services. The company primarily serves individuals, healthcare facilities, and professionals by providing products such as mobility aids, respiratory devices, and various home care solutions. BLC is committed to enhancing the quality of life for patients through its comprehensive range of medical equipment and personalized services.

How the Company Makes Money

Bastide le Confort Medical generates revenue through multiple streams including the sale and rental of medical equipment, such as wheelchairs, hospital beds, and respiratory devices. Additionally, the company earns income from providing home healthcare services, which include home-based treatments and support for chronic conditions. BLC also partners with healthcare institutions and insurance companies to supply and manage medical equipment and services, further contributing to its revenue. The company's growth is supported by its strategic acquisitions and expansion into new geographical markets, enhancing its distribution network and service offerings.

Bastide le Confort Medical Financial Statement Overview

Summary

Bastide le Confort Medical shows growth in revenue and operational cash flow, but profitability has been inconsistent with recent net losses. The high leverage and fluctuating free cash flows present financial risks that should be monitored closely.

Income Statement

The company experienced steady revenue growth with a CAGR of approximately 9.5% over the past five years, although the recent year saw a slight decrease in gross profit margin. The net income turned negative in the latest year, indicating profitability challenges that need addressing.

Balance Sheet

The company maintains a high debt-to-equity ratio of 5.12 in 2024, indicating significant leverage which poses risk. However, the equity ratio has been relatively stable, showing some level of balance in the capital structure.

Cash Flow

Free cash flow has been volatile but positive in recent years, with a significant drop from 2023 to 2024. The operating cash flow remains strong relative to net income, although the free cash flow to net income ratio is concerning due to the negative net income.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	540.26M	529.75M	508.03M	468.30M	444.07M	382.71M
Gross Profit	51.59M	46.83M	333.73M	306.80M	280.26M	251.61M
EBITDA	114.74M	107.20M	82.36M	79.51M	80.19M	66.67M
Net Income	1.71M	-900.00K	16.07M	13.68M	13.45M	11.60M
Balance Sheet
Total Assets	675.97M	647.07M	657.08M	632.55M	569.11M	506.00M
Cash, Cash Equivalents and Short-Term Investments	31.30M	23.62M	36.71M	22.13M	33.74M	35.42M
Total Debt	420.68M	408.65M	427.39M	419.23M	357.62M	306.29M
Total Liabilities	598.33M	566.34M	568.99M	545.89M	484.05M	426.38M
Stockholders Equity	76.08M	79.77M	87.65M	84.56M	81.31M	75.67M
Cash Flow
Free Cash Flow	14.98M	10.64M	36.65M	-6.51M	19.62M	-179.00K
Operating Cash Flow	82.03M	66.04M	90.28M	46.76M	66.13M	39.61M
Investing Cash Flow	-66.38M	-43.65M	-76.27M	-104.74M	-73.45M	-50.55M
Financing Cash Flow	-20.72M	-35.55M	7.53M	39.81M	9.65M	25.87M

Bastide le Confort Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Positive. The current price of 29.55 is above the 20-day moving average (MA) of 29.15, above the 50-day MA of 28.07, and above the 200-day MA of 23.78, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 54.05 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BLC.

Bastide le Confort Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNA	74 Outperform	€258.42M	11.62	7.12%	2.62%	9.58%	-6.69%
ALERS	67 Neutral	€252.64M	63.30	2.27%	―	19.15%	-20.71%
AMPLI	64 Neutral	€292.93M	268.72	1.15%	―	16.83%	―
BLC	63 Neutral	€215.99M	128.20	11.71%	―	3.24%	-75.05%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%

Bastide le Confort Medical Corporate Events

Bastide Group Releases Semi-Annual Financial Report

The Bastide Group has released its semi-annual financial report for December 31, 2024, making it available to the public and filing it with the Autorité des Marchés Financiers. This report can be accessed on their website, and the next financial update will be the publication of the 3rd quarter 2024-2025 revenue on May 15, 2025. This release underscores Bastide’s commitment to transparency and may impact investor relations and market positioning.